<?xml version="1.0" encoding="UTF-8"?>
<p>This phase II study showed that treatment of untreated younger MCL patients with R‐High‐CHOP/CHASER followed by LEED HDC with ASCT resulted in high ORR and CR rates with durable PFS and OS and acceptable toxicity profiles. These results show that this regimen of R‐High‐CHOP/CHASER/LEED with ASCT can now be considered a standard treatment option in this population.</p>
